A new approach to treatment of resistant gram-positive infections: Potential impact of targeted IV to oral switch on lenght of stay

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Desai, Mohammed ^b   Franklin, Bryony Dean ^b,c   Holmes, Alison H ^a,b   Trust, Sarah ^b   Richards, Mike ^b   Jacklin, Ann ^b   Bamford, Kathleen B ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTICLE; BACTERIAL INFECTION; CELLULITIS; COMORBIDITY; DRUG ERUPTION; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; FEMALE; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INJECTION SITE EXTRAVASATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATIONAL HEALTH SERVICE; RISK ASSESSMENT; RISK REDUCTION; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; LENGTH OF STAY; MALE; TEICOPLANIN; VANCOMYCIN;

EID: 33746422943     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-94     Document Type: Article

References (19)

1. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, Heine H, Monnickendam MA, Barker KF, James D, George RC: Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. British Medical Journal 2000, 320:213-6.
2. Fergie JE, Pucell K: Infections in South Texas children. Pediatric Infectious Disease Journal 2001, 20:860-3.
3. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Journal of the American Medical Association 1998, 279:593-8.
4. Health Protection Agency: Surveillance of Surgical Site Infection in English Hospitals 1997-2002. Department of Health, London; 2003.
5. Rojo D, Pinedo A, Clavijo E, Garcia-Rodriguez A, Garcia V: Analysis of risk factors associated with nosocomial bacteraemias. Journal of Hospital Infection 1999, 42:135-41.
6. Fernandez-Guerrero ML, Verdejo C, Azofra J, de Gorgolas M: Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clinical Infectious Diseases 1995, 20:16-23.
7. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ: Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. American Journal of Medicine 1987, 83:1091-7.
8. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH: Nephrotoxicity of vancomycin alone and with an aminoglycoside. Journal of Antimcrobial Chemotherapy 1990, 25:679-87.
9. Parker SE, Nathwani D, O'Reilly D, Parkinson S, Davey PG: Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient. Journal of Antimicrobial Chemotherapy 1998, 42:373-80.
10. Coello R, Charlett A, Ward V, Wilson J, Pearson A, Sedgwick J, Borriello P: Device-related sources of bacteraemia in English hospitals-opportunities for the prevention of hospital-acquired bacteraemia. Journal of Hospital Infection 2003, 53:46-57.
11. Chee HP, Dean B: Evaluation of an antibiotic 'IV to oral' switch on an orthopaedics ward. Pharmacy World and Science 2002, 24:A48.
12. Laing RBS, Mackenzie AR, Shaw H, Gould IM, Douglas JG: The effect of intravenous-to-oral-switch guidelines on the use of parenteral antimicrobials in medical wards. Journal of Antimicrobial Chemotherapy 1998, 42:107-111.
13. Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, Speelman P: Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. Journal of Antimicrobial Chemotherapy 1999, 43:601-606.
14. Wilcox M, Nathwani D, Dryden M: Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. Journal of Antimicrobial Chemotherapy 2004, 53:335-44.
15. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderkind RG: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-97.
16. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP: Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. Journal of Antimicrobial Chemotherapy 2002, 50:742-746.
17. Dean B, Lawson W, Jacklin A, Tom Rogers, Berge Azadian, Alison Holmes: The use of serial point prevalence studies to investigate antiinfective prescribing. International Journal of Pharmacy Practice 2003, 10:121-5.
18. Parodi S, Rhew DC, Goetz MB: Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. Journal of Managed Care Pharmacy 2003, 9:317-26.
19. Nathwani D, Barlow GD, Ajdukiewicz K, Gray K, Morrison J, Clift B, Frances AJ, Davey P: Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. Journal of Antimicrobial Chemotherapy 2003, 51:391-6.